Hospice News reports that a New Mexico hospice plans grant-supported psychedelic-assisted therapies, including ketamine and psilocybin, for terminally ill patients.
Hospice News reports planned treatment offering
Hospice News reports that a New Mexico-based hospice has announced plans to begin offering psychedelic-assisted therapies to terminally ill patients. According to Hospice News, the planned therapies include ketamine and psilocybin.
The source describes this as an announced program that the hospice will begin offering, rather than as an existing service already in operation. Hospice News does not provide further details in the supplied extract about when the program will start or how patients may access it.
Grant funding supports the program
According to Hospice News, grant funding supports the planned program. The supplied extract does not identify the grant source, the amount of funding, or the duration of support.
Hospice News states that the program aims to address existential distress, anxiety, and depression. The source says those aims apply to terminally ill patients and their families.
Treatments named in the announcement
Hospice News identifies ketamine and psilocybin as psychedelic-assisted therapies included in the planned offering. The supplied extract does not describe how either treatment would be delivered, what eligibility requirements may apply, or what services may be available to family members.
The announcement concerns a hospice setting and terminally ill patients, according to Hospice News. The source does not state whether the program will be available beyond that setting or patient group.
What this means for New Mexico patients
For people looking for treatment locally, this directory lists 19 published clinics in New Mexico. Hospice News’ report concerns a planned hospice program for terminally ill patients and families, supported by grant funding, and does not establish broader availability of the therapies described.
This is general information, not medical advice.
More New Mexico reporting on treatment updates.
This report is educational and is not medical advice. Coverage, availability and eligibility can change; verify details with the named source or your care team.